nach oben

Documenta Ophthalmologica

Erschienen in:

01.08.2014 | Original Research Article

Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion

verfasst von: Ivana Gardašević Topčić, Maja Šuštar, Jelka Brecelj, Marko Hawlina, Polona Jaki Mekjavić

Erschienen in: Documenta Ophthalmologica | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate intravitreal bevacizumab (IVB) treatment in patients with central retinal vein occlusion (CRVO) by spectral domain optical coherence tomography (OCT) and electroretinography (ERG).

Methods

Twenty-two CRVO patients were treated with IVB injections and followed for 1 year. Morphological effect of treatment was observed with fluorescent angiography and OCT. Functional effect was followed with best corrected visual acuity (BCVA) and ERG: combined rod-cone response of the standard full-field ERG (dark adapted 3.0 ERG), photopic negative response (PhNR), and pattern ERG (PERG).

Results

Best corrected visual acuity (BCVA) improved by 18.2 letters after 6 months (p ≤ 0.001) and additional 4.7 letters by the 12th month (p ≤ 0.001). The central retinal thickness of 829.8 ± 256.7 μm decreased to 398.8 ± 230 μm (p ≤ 0.001) after 6 months and to 303.7 ± 128.9 μm during the following 6 months (p ≤ 0.001). The total macular volume (14.4 ± 4.2 mm³) decreased to 9.6 ± 3.2 mm³ and 8.5 ± 2.0 mm³ after 6 months and 1 year of treatment, respectively (p ≤ 0.001). Electrophysiological measures improved significantly after 6 months and 1 year of treatment: the a-wave implicit time of dark adapted 3.0 ERG from 25.6 ± 2.3 to 24.1 ± 2.1 and 24.1 ± 2.0 ms (p ≤ 0.01); the PhNR from −5.9 ± 6.6 to −9.4 ± 6.1 and −10.4 ± 4.6 µV (p ≤ 0.05); the PERG P50 amplitude from 0.2 ± 0.3 to 0.9 ± 0.6 and 1.1 ± 0.6 µV (p ≤ 0.001); and N95 amplitude from 0.4 ± 0.6 to 1.2 ± 0.9 and 1.6 ± 0.9 µV (p ≤ 0.001).

Conclusions

Intravitreal bevacizumab (IVB) treatment of macular edema due to CRVO improved standard morphological measures and the electrophysiological function of outer and inner retinal layers, which was most evident in central retina.

Rogers S, McIntosh RL, Cheung N et al (2010) The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 117(313–9):e1. doi:10.1016/j.ophtha.2009.07.017 PubMed

Mitchell P, Smith W, Chang A (1996) Prevalence and associations of retinal vein occlusion in Australia. The Blue Mountains Eye Study. Arch Ophthalmol 114:1243–1247PubMedCrossRef

Mohamed Q, McIntosh RL, Saw SM, Wong TY (2007) Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 114(507–19):524. doi:10.1016/j.ophtha.2006.11.011

Karia N (2010) Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 4:809–816PubMedCentralPubMedCrossRef

Noma H, Funatsu H, Mimura T et al (2010) Increase of vascular endothelial growth factor and interleukin-6 in the aqueous humour of patients with macular oedema and central retinal vein occlusion. Acta Ophthalmol 88:646–651. doi:10.1111/j.1755-3768.2009.01524.x PubMedCrossRef

Coscas G, Loewenstein A, Augustin A et al (2011) Management of retinal vein occlusion–consensus document. Ophthalmologica 226:4–28. doi:10.1159/000327391 PubMedCrossRef

Mekjavic PJ, Kraut A, Urbancic M et al (2011) Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections. Acta Ophthalmol 89:647–653. doi:10.1111/j.1755-3768.2009.01740.x PubMedCrossRef

Algvere PV, Epstein D, von Wendt G et al (2011) Intravitreal bevacizumab in central retinal vein occlusion: 18-month results of a prospective clinical trial. Eur J Ophthalmol 21:789–795. doi:10.5301/EJO.2011.6522 PubMedCrossRef

Epstein DL, Algvere PV, von Wendt G et al (2012) Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study. Ophthalmology 119:2587–2591. doi:10.1016/j.ophtha.2012.06.037 PubMedCrossRef

10.

Rensch F, Jonas JB, Spandau UHM (2009) Early intravitreal bevacizumab for non-ischaemic central retinal vein occlusion. Acta Ophthalmol 87:77–81. doi:10.1111/j.1755-3768.2008.01313.x PubMedCrossRef

11.

Figueroa MS, Contreras I, Noval S, Arruabarrena C (2010) Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 94:1052–1056. doi:10.1136/bjo.2009.173732 PubMedCrossRef

12.

Costa RA, Jorge R, Calucci D et al (2007) Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: iBeVO study. Retina 27:141–149. doi:10.1097/IAE.0b013e31802eff83 PubMedCrossRef

13.

Pai SA, Shetty R, Vijayan PB et al (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143:601–606. doi:10.1016/j.ajo.2006.12.037 PubMedCrossRef

14.

Shetty R, Pai SA, Vincent A et al (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116:129–135. doi:10.1007/s10633-007-9090-9 PubMedCrossRef

15.

Moschos MM, Moschos M (2008) Intraocular bevacizumab for macular edema due to CRVO. A multifocal-ERG and OCT study. Doc Ophthalmol 116:147–152. doi:10.1007/s10633-007-9110-9 PubMedCrossRef

16.

Moon CH, Ahn S, Ohn Y-H II et al (2013) Visual prognostic value of photopic negative response and optical coherence tomography in central retinal vein occlusion after anti-VEGF treatment. Doc Ophthalmol 126:211–219. doi:10.1007/s10633-013-9379-9 PubMedCrossRef

17.

Morrell AJ, Thompson DA, Gibson JM et al (1991) Electroretinography as a prognostic indicator or neovascularisation in CRVO. Eye (Lond) 5(Pt 3):362–368. doi:10.1038/eye.1991.58 CrossRef

18.

Sabates R, Hirose T, McMeel JW (1983) Electroretinography in the prognosis and classification of central retinal vein occlusion. Arch Ophthalmol 101:232–235. doi:10.1001/archopht.1983.01040010234010 PubMedCrossRef

19.

Hayreh SS, Klugman MR, Podhajsky P, Kolder HE (1989) Electroretinography in central retinal vein occlusion. Correlation of electroretinographic changes with pupillary abnormalities. Graefes Arch Clin Exp Ophthalmol 227:549–561PubMedCrossRef

20.

Johnson MA, Marcus S, Elman MJ, McPhee TJ (1988) Neovascularization in central retinal vein occlusion: electroretinographic findings. Arch Ophthalmol 106:348–352PubMedCrossRef

21.

Robson JG, Frishman LJ (1999) Dissecting the dark-adapted electroretinogram. Doc Ophthalmol 95:187–215CrossRef

22.

Brown KT (1968) The electroretinogram: its components and their origins. Vis Res 8:633–677PubMedCrossRef

23.

Chen H, Wu D, Huang S, Yan H (2006) The photopic negative response of the flash electroretinogram in retinal vein occlusion. Doc Ophthalmol 113:53–59. doi:10.1007/s10633-006-9015-z PubMedCrossRef

24.

Matsui Y, Katsumi O, McMeel JW, Hirose T (1994) Prognostic value of initial electroretinogram in central retinal vein obstruction. Graefes Arch Clin Exp Ophthalmol 232:75–81. doi:10.1007/BF00171667 PubMedCrossRef

25.

Matsui Y, Katsumi O, Sakaue H, Hirose T (1994) Electroretinogram b/a wave ratio improvement in central retinal vein obstruction. Br J Ophthalmol 78:191–198PubMedCentralPubMedCrossRef

26.

Williamson TH (1997) Central retinal vein occlusion: what’s the story? Br J Ophthalmol 81:698–704PubMedCentralPubMedCrossRef

27.

Moschos M, Brouzas D, Moschou M, Theodossiadis G (1999) The a- and b-wave latencies as a prognostic indicator of neovascularisation in central retinal vein occlusion. Doc Ophthalmol 99:123–133PubMedCrossRef

28.

Viswanathan S, Frishman LJ, Robson JG, Walters JW (2001) The photopic negative response of the flash electroretinogram in primary open angle glaucoma. Invest Ophthalmol Vis Sci 42:514–522PubMed

29.

Viswanathan S, Frishman LJ, Robson JG et al (1999) The photopic negative response of the macaque electroretinogram: reduction by experimental glaucoma. Invest Ophthalmol Vis Sci 40:1124–1136PubMed

30.

Viswanathan S, Frishman LJ, Robson JG (2000) The uniform field and pattern ERG in macaques with experimental glaucoma: removal of spiking activity. Invest Ophthalmol Vis Sci 41:2797–2810PubMed

31.

Holder GE (1987) Significance of abnormal pattern electroretinography in anterior visual pathway dysfunction. Br J Ophthalmol 71:166–171PubMedCentralPubMedCrossRef

32.

Ryan S, Arden GB (1988) Electrophysiological discrimination between retinal and optic nerve disorders. Doc Ophthalmol 68:247–255PubMedCrossRef

33.

Central Vein Occlusion Study Group (1995) A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion. The Central Vein Occlusion Study Group N report. Ophthalmology 102:1434–1444

34.

Hawlina M, Konec B (1992) New noncorneal HK-loop electrode for clinical electroretinography. Doc Ophthalmol 81:253–259PubMedCrossRef

35.

Marmor MF, Fulton AB, Holder GE et al (2009) ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 118:69–77. doi:10.1007/s10633-008-9155-4 PubMedCrossRef

36.

Hood DC, Bach M, Brigell M et al (2008) ISCEV guidelines for clinical multifocal electroretinography (2007 edition). Doc Ophthalmol 116:1–11. doi:10.1007/s10633-007-9089-2 PubMedCentralPubMedCrossRef

37.

Bach M, Brigell MG, Hawlina M et al (2013) ISCEV standard for clinical pattern electroretinography (PERG): 2012 update. Doc Ophthalmol 126:1–7. doi:10.1007/s10633-012-9353-y PubMedCrossRef

38.

Sustar M, Cvenkel B, Brecelj J (2009) The effect of broadband and monochromatic stimuli on the photopic negative response of the electroretinogram in normal subjects and in open-angle glaucoma patients. Doc Ophthalmol 118:167–177. doi:10.1007/s10633-008-9150-9 PubMedCrossRef

39.

Aiello LP, Brucker AJ, Chang S et al (2004) Evolving guidelines for intravitreous injections. Retina 24:S3–S19PubMedCrossRef

40.

McIntosh RL, Rogers SL, Lim L et al (2010) Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 117(1113–1123):e15. doi:10.1016/j.ophtha.2010.01.060 PubMed

41.

Arden GB, Hamilton AM, Wilson-Holt J et al (1986) Pattern electroretinograms become abnormal when background diabetic retinopathy deteriorates to a preproliferative stage: possible use as a screening test. Br J Ophthalmol 70:330–335PubMedCentralPubMedCrossRef

42.

Coupland SG (1987) A comparison of oscillatory potential and pattern electroretinogram measures in diabetic retinopathy. Doc Ophthalmol 66:207–218PubMedCrossRef

43.

Falsini B, Porciatti V, Scalia G et al (1989) Steady-state pattern electroretinogram in insulin-dependent diabetics with no or minimal retinopathy. Doc Ophthalmol 73:193–200PubMedCrossRef

44.

Holder GE (2001) Pattern electroretinography (PERG) and an integrated approach to visual pathway diagnosis. Prog Retin Eye Res 20:531–561PubMedCrossRef

45.

Breton ME, Schueller AW, Montzka DP (1991) Electroretinogram b-wave implicit time and b/a wave ratio as a function of intensity in central retinal vein occlusion. Ophthalmology 98:1845–1853PubMedCrossRef

46.

Kaye SB, Harding SP (1988) Early electroretinography in unilateral central retinal vein occlusion as a predictor of rubeosis iridis. Arch Ophthalmol 106:353–356. doi:10.1001/archopht.1988.01060130379026 PubMedCrossRef

47.

Campochiaro PA, Bhisitkul RB, Shapiro H, Rubio RG (2013) Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 120:795–802. doi:10.1016/j.ophtha.2012.09.032 PubMedCrossRef

Titel: Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion
verfasst von: Ivana Gardašević Topčić
Maja Šuštar
Jelka Brecelj
Marko Hawlina
Polona Jaki Mekjavić
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Documenta Ophthalmologica / Ausgabe 1/2014
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI: https://doi.org/10.1007/s10633-014-9445-y

Neu im Fachgebiet Augenheilkunde

08.04.2024 | Therapieverfahren in der Augenheilkunde | CME

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Morphological and electrophysiological outcome in prospective intravitreal bevacizumab treatment of macular edema secondary to central retinal vein occlusion

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2014

Multifocal electroretinogram responses in Nepalese diabetic patients without retinopathy

Estimating ON and OFF contributions to the photopic hill: normative data and clinical applications

Improved measurement of intersession latency in mfVEPs

Changes in the harmonic components of the flicker electroretinogram during light adaptation

Autosomal recessive bestrophinopathy associated with angle-closure glaucoma

Erratum to: Multifocal electroretinogram responses in Nepalese diabetic patients without retinopathy

Neu im Fachgebiet Augenheilkunde

Ophthalmika in der Schwangerschaft

Operative Therapie und Keimnachweis bei endogener Endophthalmitis

Bakterielle endogene Endophthalmitis

Bestmögliche Wundheilung der Kornea dank optimaler pharmakologischer Therapie

Update Augenheilkunde